BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 18990068)

  • 21. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Invasive aspergillosis in hematooncological patients: advantages and disadvantages of various diagnostic methods, treatment options and financial costs of therapy].
    Rácil Z; Mayer J; Kocmanová I; Wagnerová B; Winterová J; Folber F; Lengerová M; Moulis M; Zácková D; Smardová L; Janíková A; Navrátil M; Dvoráková D; Vorlícek J
    Vnitr Lek; 2008 Feb; 54(2):157-68. PubMed ID: 23687707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
    Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
    J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey.
    Sinkó J; Csomor J; Nikolova R; Lueff S; Kriván G; Reményi P; Bátai A; Masszi T
    Transpl Infect Dis; 2008 Apr; 10(2):106-9. PubMed ID: 17605727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
    Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
    Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients.
    Jantunen E; Nihtinen A; Anttila VJ
    Transpl Infect Dis; 2008 Jun; 10(3):156-61. PubMed ID: 18266785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between high-resolution computed tomography and galactomannan antigenemia in adult hematologic patients at risk for invasive aspergillosis.
    Hidalgo A; Parody R; Martino R; Sánchez F; Franquet T; Giménez A; Blancas C
    Eur J Radiol; 2009 Jul; 71(1):55-60. PubMed ID: 18468830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases.
    Mouas H; Lutsar I; Dupont B; Fain O; Herbrecht R; Lescure FX; Lortholary O;
    Clin Infect Dis; 2005 Apr; 40(8):1141-7. PubMed ID: 15791514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A; Hoffman J; Sheth A
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic effects of aspergillosis management in high-risk patients.
    Leather H
    Manag Care Interface; 2005 Apr; 18(4):46-52. PubMed ID: 15889762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
    Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
    Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
    Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis.
    Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II
    Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; O'Brien S; Kontoyiannis DP; Giles F; Zhou X; Lim J; Bekele BN; Faderl S; Cortes J; Pierce S; Leitz GJ; Raad I; Estey E
    Cancer; 2004 Feb; 100(3):568-73. PubMed ID: 14745874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
    Kaya Z; Gursel T; Kocak U; Aral YZ; Kalkanci A; Albayrak M
    Pediatr Blood Cancer; 2009 Apr; 52(4):470-5. PubMed ID: 19058205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting.
    White PL; Linton CJ; Perry MD; Johnson EM; Barnes RA
    Clin Infect Dis; 2006 Feb; 42(4):479-86. PubMed ID: 16421791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive aspergillosis in pediatric oncology patients: a rare event with poor prognosis--case analysis to plan better targeted prophylactic or therapeutic measurement.
    Babor F; Schuster F; Mackenzie C; Meisel R; Schaper J; Sabir H; Siepermann M; Wessalowski R; Janßen G; Borkhardt A; Laws HJ
    Klin Padiatr; 2012 Apr; 224(3):160-5. PubMed ID: 22504775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.